Literature DB >> 25340297

Pediatric critical care physician-administered procedural sedation using propofol: a report from the Pediatric Sedation Research Consortium Database.

Pradip P Kamat1, Courtney E McCracken, Scott E Gillespie, James D Fortenberry, Jana A Stockwell, Joseph P Cravero, Kiran B Hebbar.   

Abstract

OBJECTIVE: Increasing demand for pediatric procedural sedation has resulted in a marked increase in provision of pediatric procedural sedation by pediatric critical care physicians both inside and outside of the ICU. Reported experience of pediatric critical care physicians-administered pediatric procedural sedation is limited. We used the Pediatric Sedation Research Consortium database to evaluate a multicenter experience with propofol by pediatric critical care physicians in all settings.
SETTING: Review of national Pediatric Sedation Research Consortium database to identify pediatric procedural sedation provided by pediatric critical care physicians from 2007 to 2012. Demographic and clinical data were collected to describe pediatric procedural sedation selection, location, and delivery. Multivariable logistic regression analysis was performed to identify risk factors associated with pediatric procedural sedation-related adverse events and complications.
MEASUREMENTS AND MAIN RESULTS: A total of 91,189 pediatric procedural sedation performed by pediatric critical care physicians using propofol were included in the database. Median age was 60.0 months (range, 0-264 months; interquartile range, 34.0-132.0); 81.9% of patients were American Society of Anesthesiologists class I or II. Most sedations were performed in dedicated sedation or radiology units (80.9%). Procedures were successfully completed in 99.9% of patients. A propofol bolus alone was used in 52.8%, and 41.7% received bolus plus continuous infusion. Commonly used adjunctive medications were lidocaine (35.3%), opioids (23.3%), and benzodiazepines (16.4%). Overall adverse event incidence was 5.0% (95% CI, 4.9-5.2%), which included airway obstruction (1.6%), desaturation (1.5%), coughing (1.0%), and emergent airway intervention (0.7%). No deaths occurred; a single cardiac arrest was reported in a 13-month-old child receiving propofol and ketamine, with no untoward neurologic sequelae. Risk factors associated with adverse event included: location of sedation, number of adjunctive medications, upper and lower respiratory diagnosis, prematurity diagnosis, weight, American Society of Anesthesiologists status, and painful procedure.
CONCLUSIONS: Pediatric procedural sedation using propofol can be provided by pediatric critical care physicians effectively and with a low incidence of adverse events.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25340297     DOI: 10.1097/PCC.0000000000000273

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  20 in total

Review 1.  Propofol: a review of its role in pediatric anesthesia and sedation.

Authors:  Vidya Chidambaran; Andrew Costandi; Ajay D'Mello
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

2.  Experience with the use of propofol for radiologic imaging in infants younger than 6 months of age.

Authors:  Elan Jenkins; Kiran B Hebbar; Katie K Karaga; Daniel A Hirsh; James D Fortenberry; Courtney E McCracken; Stephen F Simoneaux; Michael D Mallory; Pradip P Kamat
Journal:  Pediatr Radiol       Date:  2017-05-09

Review 3.  Pharmacologic Considerations for Pediatric Sedation and Anesthesia Outside the Operating Room: A Review for Anesthesia and Non-Anesthesia Providers.

Authors:  Narjeet Khurmi; Perene Patel; Molly Kraus; Terrence Trentman
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

4.  A Comparison of Safety and Efficacy of Dexmedetomidine and Propofol in Children with Autism and Autism Spectrum Disorders Undergoing Magnetic Resonance Imaging.

Authors:  Kamal Abulebda; Ryan Louer; Riad Lutfi; Sheikh Sohail Ahmed
Journal:  J Autism Dev Disord       Date:  2018-09

5.  Feasibility of measuring memory response to increasing dexmedetomidine sedation in children.

Authors:  K P Mason; E R Kelhoffer; R Prescilla; M Mehta; J C Root; V J Young; F Robinson; R A Veselis
Journal:  Br J Anaesth       Date:  2017-02       Impact factor: 9.166

6.  Pediatric Procedural Sedation Using the Combination of Ketamine and Propofol Outside of the Emergency Department: A Report From the Pediatric Sedation Research Consortium.

Authors:  Jocelyn R Grunwell; Curtis Travers; Anne G Stormorken; Patricia D Scherrer; Corrie E Chumpitazi; Jana A Stockwell; Mark G Roback; Joseph Cravero; Pradip P Kamat
Journal:  Pediatr Crit Care Med       Date:  2017-08       Impact factor: 3.624

7.  Outcomes following implementation of a pediatric procedural sedation guide for referral to general anesthesia for magnetic resonance imaging studies.

Authors:  Jocelyn R Grunwell; Neelima K Marupudi; Rohan V Gupta; Curtis D Travers; Courtney E McCracken; Julie L Williamson; Jana A Stockwell; James D Fortenberry; Kevin Couloures; Joseph Cravero; Pradip P Kamat
Journal:  Paediatr Anaesth       Date:  2016-04-07       Impact factor: 2.556

8.  Procedural Sedation Outside of the Operating Room Using Ketamine in 22,645 Children: A Report From the Pediatric Sedation Research Consortium.

Authors:  Jocelyn R Grunwell; Curtis Travers; Courtney E McCracken; Patricia D Scherrer; Anne G Stormorken; Corrie E Chumpitazi; Mark G Roback; Jana A Stockwell; Pradip P Kamat
Journal:  Pediatr Crit Care Med       Date:  2016-12       Impact factor: 3.624

9.  Propofol sedation in children: sleep trumps amnesia.

Authors:  Robert Veselis; Eric Kelhoffer; Meghana Mehta; James C Root; Fay Robinson; Keira P Mason
Journal:  Sleep Med       Date:  2016-10-22       Impact factor: 3.492

10.  Adjuvant lidocaine to a propofol-ketamine-based sedation regimen for bone marrow aspirates and biopsy in the pediatric population.

Authors:  Jeffrey S Yu; Ryan Louer; Riad Lutfi; Samer Abu-Sultaneh; Mouhammad Yabrodi; Janine Zee-Cheng; Kamal Abulebda
Journal:  Eur J Pediatr       Date:  2020-06-16       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.